Modulation by conagenin of inflammatory mediator productions in mice given 5-fluorouracil

Anticancer Research

Volumn 17, Issue 2 A, 1997, Pages 917-922

  Kawatsu, Masaji ^a   Yamashita, Takashi ^a   Ishizuka, Masaaki ^a   Takeuchi, Tomio ^a  

^a Numazu Bio Medical Research Institute   (Japan)

Author keywords

5 fluorouracil; Conagenin; Interleukin 1 ; Interleukin 10; Interleukin 4; Prostaglandin E2

Indexed keywords

CONAGENIN; FLUOROURACIL; INTERLEUKIN 10; INTERLEUKIN 1ALPHA; INTERLEUKIN 4; N [2,4 DIHYDROXY 3 METHYLPENTANOYL] 2 METHYLSERINE; PROSTAGLANDIN E2; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DIARRHEA; FEMALE; INFLAMMATION; MEDIATOR; MODULATION; MOUSE; NONHUMAN; PERITONEAL EXUDATE CELL; PEYER PATCH; PRIORITY JOURNAL; SPLEEN CELL;

ADJUVANTS, IMMUNOLOGIC; ANIMALS; ANTIMETABOLITES, ANTINEOPLASTIC; CYTOKINES; DINOPROSTONE; FEMALE; FLUOROURACIL; INFLAMMATION MEDIATORS; MICE; SERINE;

EID: 0030932649     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (36)

1. Crem JL, Shoemaker DD, Petrelli NJ and Douglass, Jr HO : Severe and fatal toxic effects observed in treatment with high- and low dose leucovorin plus 5-fluorouracil for colorectal carcinoma. Cancer Treat Rep 71: 1122, 1987.
2. Arbuck SG: Overview of clinical trials using 5-fluorouracil and leucovorin for the treatment of colorectal carcinoma. Cancer 63: 1036-1044, 1990.
3. Pazdur R, Ajani JA, Patt YZ, Winn R, Jackson D, Shepard B, DuBrow R, Campos L, Quaraishi M, Faintudi J, Abbruzzese JL, Gutterman, J andLevin, B: Phase III study of fluorouracil and recombinant Interferon alpha-2a in previously untreated advanced colorectal carcinoma. J Clin Oncol 8: 2027-2031, 1990.
4. Spears CP, Shahinian AH, Moran RG, Heidelberger C and Corbett TH: In vivo kinetics of thymidylate synthase inhibition in 5-fluorouracil sensitive and -resistant murine colon adenocarcinoma. Cancer Res 43: 450-456, 1982.
5. Spears CP, Gustavsson BG, Mitchell MS, Spicer D, Berne M, Bernstein L and Danenberg PV: Thymidylale synthetase inhibition in malignant tumors and normal liver of patients given intravenous 5-fluurouracil. Cancer Res 44: 4144-4150, 1984.
6. Wilkinson DS, Tlsty TD and Hanas RJ: The inhibition of ribosomal RNA synthesis and maturation in Novikoff hepatoma cells by 5-fluorouridine. Cancer Res 35: 3014-3020, 1975.
7. Carrico CK and Glazer RI: Effects of 5-fluorouracil on the synthesis and translation of polyadenylic acid containing RNA from regenerating rat liver. Cancer Res 30: 3694-4701, 1979.
8. Swayer RC, Stolfi RL, Martin DS and Spiegelman S: Incorporation of fluorouracil into murine bone marrow DNA in vitro. Cancer Res 44: 1847-1851, 1984.
9. Houghton, JA, Houghton PJ and Wooten RS: Mechanism of induction of gastrointestinal toxicity in the mouse by 5-fluorouracil, 5-fluorouridine, and 5-fluoro-2-deoxyuridine. Cancer Res 39: 2406-2413, 1979.
10. Shirasaka T, Shimamoto Y and Fukushima M : Inhibition by oxonic acid of gastrointestinal toxicity of 5-fluorouracil without loss of its antitumor activity in rats. Cancer Res 53: 4004-4009, 1993.
11. Cascinu S, Fedeli A, Fedeli SL and Catulano G: Octoreotide versus loperamide in the treatment of fluorouracil-induced diarrhea: a randomized trial. J Clin Oncol 11: 148-151, 1993.
12. Wadler S, Haynes H and Wiernik PH: Phase I trial of the somatostatin analog octreotide acetate in the treatment of fluoropyrimidine-induced diarrhea. J Clin Oncol 13: 222-226, 1995.
13. Yamashita T, Iijima M, Nakamura H, Isshiki K, Naganawa H, Hattori S, Hamada M, Ishizuka M, Takeuchi T and Iitaka Y: Conagenin, a low molecular weight immunomodulator produced by Streptomyces roseosporus. J Antibiotics 44: 557-559, 1991.
14. Kawatsu M, Yamashita T, Ishizuka M and Takeuchi T: Improvement of intestinal toxicity of 5-fluorouracil by conagenin, a low molecular immunomodulator. Anticancer Res 16: 2937-2942, 1996.
15. Kawatsu M, Yamashita T, Osono M, Ishizuka M and Takeuchi T: T cell activation by conagenin in mice. J Antibiotics 46: 1687-1691, 1993.
16. Kawatsu M, Yamashita T, Osono M, Masuda T, Ishizuka M and Takeuchi T: Effect of conagenin in tumor bearing mice antitumor activity, generation of effector cells and cytokine production. J Antibiotics 47: 1692-1698, 1993.
17. Kawatsu M, Yamashita T, Ishizuka M and Takeuchi T: Effect of conagenin on thrombocytopenia induced by antitumor agents in mice. J. Antibiotics 47: 1123-1129, 1994.
18. Ishizuka M, Yamashita T, Kawatsu M, Takeuchi T, Katsumi T and Shiraishi T: Conagenin, a low molecular weight immunomodulator produced by Streptomyces roseosporus, on murine tumors and platelet production. In: Recent advances in chemotherapy, proceedings of the 18th international congress of chemotherapy (Einhorn J, Nord CE and Norrby SR, eds). Washington D.C., American Society for Microbiology, 1993, p310.
19. Kawatsu M, Yamashita T, Ishizuka M and Takeuchi T: Improvement of efficacy of antitumor agents by conagenin. J Antibiotics 48: 222-225, 1995.
20. Matsushima K and Yashumoto K: Cytokinos causing cachexia in tumor bearing hosts. Ann Cancer Res Ther 1: 35-37, 1992.
21. Langstein HN, Doherty CM, Fraker DL, Buresh CM and Norton JA : The role of γ-interferon and tumor necrosis factor α in an experimental rat model of cancer cachexia. Cancer Res 57: 2302-2306, 1991.
22. Langstein HN and Norton JA: Mechanism of cancer cachexia. Hematology/Oncology Clinics of North America 5: 103-123, 1991.
23. Goodwin JS and Ceuppens J: Regulation of the immune response by prostaglandins. J Clin Immunol 3: 295-315, 1983.
24. Alleva DG, Burger CJ and Elgert KD: Interferon-γ reduces tumor induced Ia-macrophage-mediated suppression: Role of prostaglandin E2, Ia and tumor necrosis factor-α. Immunopharmacol 25: 215-227, 1993.
25. Massague J: The transforming growth factor-β family. Ann Rev Cell Biol: 597-641, 1990.
26. Salvemini D, Misko TP, Masferrer JL, Seibert K, Currie MG and Needleman P: Nitric oxide activates cyclooxygenase enxymes. Proc Natl Acad Sci USA 90: 7240-7244, 1993.
27. Essner R, Rhoades K, McBride WH, Morton DL and Economou JS : IL-4 down-regulates IL-1 and TNF gene expression in human monocytes. J Immunol 142: 3857-3861, 1989.
28. Wang P, Wu P, Siegel MI, Egan RW and Billah MM: IL-10 inhibits transcription of cytokine genes in human peripheral blood mononuclear cells: J Immunol 153: 811-816, 1994.
29. Niiro H, Otsuka T, Kuga S, Nemoto Y, Abe M, Hara N, Nakano T, Oga T and Niho Y: IL-10 inhibits prostaglandin E2 production by lipopolysaccharide-slimulated monocytes. Int Immunol 6: 661-661, 1994.
30. Niiro H, Otsuka T, Tanabe T, Hara S, Kuga S, Nemoto Y, Tanaka Y, Nakashima H, Kilajima S, Abe M and Niho Y: Inhibition by interleukin-10 of inducible cyclooxygenase expression in lipopolysaccharide-stimulated monocytes: Its underlying mechanism in comparison with interleukin-4. Blood 85: 3736-3745, 1995.
31. Mertz PM, Dewitt DL, Stetler-Stevenson WG and Wahl LM: Interleukin 10 suppression of monocyte prostaglandin H synthase-2. J Biol Chem 269: 21322-21329, 1994.
32. de Waal Malefyt R, Abrams J, Bennett B, Figdor CG and de Vries JE: Interleukin 10(IL-10) inhibits cytokine synthesis by human monocytes: an autoregulatory role of IL-10 produced by monocytes. J Exp Med 174: 1209-1220, 1991.
33. Izzo RS, Witkon K, Chen AI, Hadjiyane C, Weinstein MI and Pellecchia C: Interleukin-8 and neutrophil markers in colonic mucosa from patients with ulcerative colitis. Am J Gastroenterol 87: 1447-1452, 1992.
34. Isaacs KL, Sartor RB and Haskill S : Cytokine messenger RNA profiles in inflammatory bowel disease mucosa detected by polymerase chain reaction amplification. Gastroenterology 103: 1587-1595, 1992.
35. Kuhn R, Lohler J, Rennick D, Rajewsky K and Mulller W: Interleukin-10-deficient mice develop chronic enterocolitis. Cell 75: 263-274, 1993.
36. Dueno MI, Bai JC and Santangelo J: Effect of somatostatin analog on water and electolyte transport and transit time in human small bowel. Dig Dis Sci 32: 1092-1096, 1987.